126 results about "Desamethasone" patented technology

The invention provides a completely new process route for synthesizing dexamethasone and series products thereof. The invention adopts 1, 4, 9, 16-tetraene-pregna-3, 20-diketone as the original material which is modified by 9, 11bits, 16, 17 bits and 21 bits so as to obtain the dexamethasone and the series products thereof such as dexamethasone acetate and dexamethasone sodium phosphate and the like. The process has the advantage that the invention adopts the existing intermediates of manufacturers as the original material; the route is simple; the materials are available; the use of expensive accessories is avoided; the yield and the cost are dramatically better than that of the prior methods used for synthesizing the dexamethasone and derivatives thereof; moreover, the adoption of the existing intermediates realizes the combined-line prodction of the betamethasone series products and the dexamethasone series products, thus greatly reducing the manufacturing cost and the industrial manufacturing condition.

The invention provides a completely new process route for synthesizing betamethasone and series products thereof. The invention adopts 1, 4, 9, 16-tetraene-pregna-3, 20-diketone as the original material which is modified by 9, 11 bits, 16, 17 bits and 21 bits so as to obtain the betamethasone and the series products thereof such as betamethasone acetate and betamethasone sodium phosphate and the like. The process has the advantage that the invention adopts the existing intermediates of manufacturers as the original material; the route is simple; the materials are available; the use of expensive accessories is avoided; the yield and the cost are dramatically better than that of the prior methods used for synthesizing the betamethasone and derivatives thereof; moreover, the adoption of the existing intermediates realizes the combined-line production of the betamethasone series products and dexamethasone series products, thus greatly reducing the manufacturing cost and the industrial manufacturing condition.

The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as TarcevaÚ, wherein the first and second amounts or doses together comprise a therapeutically effective amount.

The present invention provides a mesenchymal stem cell adipogenic differentiation culture medium, and belongs to the technical field of stem cells. The mesenchymal stem cell adipogenic differentiation culture medium comprises a DMEM / F12 culture medium, and further comprises FBS with a volume percentage of 5-50%, glutamine with a volume percentage of 0.5-5%, antibiotic with a volume percentage of 0.5-5%, 50-500 [mu]M indometacin, 50-500 nM insulin, 5-50 nM dexamethasone, 0.5-5 [mu]M 3-isobutyl-1-methylxanthine, and 0.05-0.5 [mu]M fasudil hydrochloride. The mesenchymal stem cell adipogenic differentiation culture medium of the present invention has advantages of high inducing efficiency and the like.

The invention relates to a preparation method of a photoelectrochemical sensor for detecting dexamethasone based on in-situ generation of cadmium sulfide. The method specifically comprises the following steps: as carboxylated carbon nitride and bismuth sulfide are taken as substrate materials, and labeling a dexamethasone antibody by using titanium dioxide subjected to cadmium ion functionalization. Sodium sulfide is directly dropwise added to the electrode surface, a narrow band-gap cadmium sulfide semiconductor nanometer material with the high photoelectric conversion efficiency is generated in situ, and a photocurrent signal is generated under light source irradiation with visible wavelength. A porous titanium dioxide carrier and a cadmium sulfide energy band are well matched, so that the photoelectric conversion efficiency of the cadmium sulfide is improved, the high-sensitivity detection of dexamethasone is realized, and the detection limit is 2pg / mL.

The invention relates to a method of inducing a human fibroblast to reprogram the human fibroblast into an osteoblast by utilization of Runx2 and a low-molecular-weight compound, particularly relates to a method of inducing a human fibroblast to transdifferentiate the human fibroblast into an osteoblast under the existence of dexamethasone by utilization of Runx2 gene expression, a low-molecular-weight compound CHIR99021 and / or a low-molecular-weight compound forskolin, and belongs to the fields of cytobiology and tissue engineering. The method includes: constructing a human skin fibroblast infected by a slow virus carrying Runx2-GFP, performing transdifferentiation of the human fibroblast under the existence of the dexamethasone by utilization of the low-molecular-weight compound CHIR99021 having a concentration of 5-10 muM and the low-molecular-weight compound forskolin having a concentration of 10 muM, changing into an osteoblast inducing liquid after 7-15 days, and inducing, and the fibroblast can be induced into the osteoblast after 5-20 days. The method can obtain osteoblasts simply and rapidly and can be used for cell therapy for bone metabolic disease, fracture, and the like. A pharmaceutical composition provided by the invention can be used for research, development and production of tissue-engineered bone, brings convenience to fundamental research and brings a prospect for clinical application.

The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib and dexamethasone.

Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for treating inflammatory and autoimmune diseases, including but not limited to lupus, are disclosed.

A method for treating multiple myeloma in newly diagnosed or previously treated patients is described. The method comprises administering a composition consisting of a combination of chemotherapeutic agents of an anthracycline antibiothic, preferably entrapped in a liposome, dexamethasone, and thalidomide, and, optionally, a reduced dose of vincristine.

The present invention provides a method of inducing undifferentiated cells into induced osteoblasts. The method includes: A) a step of providing an induced osteoblast differentiation inducing agent obtained by culturing chondrocytes capable of hypertrophication in a differentiation agent producing medium containing dexamethasone, β-glycerophosphate, ascorbic acid and a serum component; and B) a step of culturing the undifferentiated cells in an undifferentiated cell culture medium containing the induced osteoblast differentiation inducing agent and a medium component, to differentiate the undifferentiated cells into the induced osteoblasts.

The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with lenalidomide and dexamethasone.

The invention discloses a method for simultaneously detecting two glucocorticoid isomerides in animal-derived food. The method separates two enantiomers of betamethasone, dexamethasone, fluorometholone and desoximetasone by adopting a conventional chromatographic column, and can detect the residual amount of betamethasone, dexamethasone, fluorometholone and desoximetasone in the animal-derived food and confirm. A C18 chromatic column is adopted for liquid chromatogram; the flow phases are respectively acetonitrile containing methyl alcohol and water containing methyl alcohol, and tandem mass spectrum detection is carried out; two enantiomers of betamethasone, dexamethasone, fluorometholone and desoximetasone can be subjected to chromatograph separation; the detection limit of dexamethasone is 0.2 micron g / kg; the detection limit of betamethasone, fluorometholone and desoximetasone is 0.4 micron g / kg; the residual amount regulatory restriction requirement at home and abroad is met; the method is simple, convenient, accurate, flexible and reliable.

The present invention provides a mesenchymal stem cell ossification osteogenic differentiation culture medium, and belongs to the technical field of stem cells. The mesenchymal stem cell ossification osteogenic differentiation culture medium comprises a DMEM / F12 culture medium, and further comprises FBS with a volume percentage of 5-50%, glutamine with a volume percentage of 0.5-5%, antibiotic with a volume percentage of 0.5-5%, 100-1000 [mu]M ascorbic acid, 5-50 mM glycerol phosphate, 5-50 nM dexamethasone, 5-50 [mu]M resveratrol, and 0.05-0.5 [mu]M puerarin. The mesenchymal stem cell ossification osteogenic differentiation culture medium of the present invention has advantages of high inducing efficiency and the like.

The invention relates to a formula for preparing an anti-eczema dermatitis product and the preparation method thereof. The invention adopts dexamethasone, menthol, phenol and boric acid compatibly for external use for the first time and provides an anti-eczema dermatitis product which also has multiple prevention functions of anti-allergy, anti-pruritus, anti-infection, and the like; the formula has the advantages of remarkable and quick antipruritic effect, strong bacteriostasis, small toxic side effect, and positive curative effect; ideal effect can be achieved when the anti-eczema dermatitis product is in direct use; more particularly, the tincture formula thereof has the advantages of stable property, simple preparation technology, safety and effectiveness, good feasibility, high repeatability, and controlled quality, and is suitable for the industrial production. The eczema dermatitis has diverse categories and etiologies, complicated disease diagnosis, and very high incidence and relapse rate; the anti-eczema dermatitis product of the invention has a plurality of usages, can enhance medical effect, is convenient to select in clinic, and can reduce the economic burden of the patients; therefore, with the number of dermatitis patients increasing year by year, the demand for therapeutic medication can be also increased; the formula and the preparation method thereof can produce greater social and economic benefits.

The invention relates to a release speed-controllable type silk fibroin nanometer microsphere loading methylprednisolone and dexamethasone. The release speed-controllable type silk fibroin nanometer microsphere comprises silk fibroin with lower and higher release speeds; after the silk fibroin with lower and higher release speeds are dissolved, the molecular weight cutoff of the silk fibroin with lower drug release speed after dialysis is 12000 to 14000; the molecular weight cutoff of the silk fibroin with higher drug release speed is 100 to 500; the average particle size of the silk fibroin nanometer microsphere loading methylprednisolone and dexamethasone is 35 to 125nm. The release speed-controllable type silk fibroin nanometer microsphere loading methylprednisolone and dexamethasone has the advantages that the action times of methylprednisolone and dexamethasone at certain dosages can be effectively controlled according to the administration time after injury, the half-life period is controlled, the medicine effect is effectively realized under the condition of joint administration, the therapy effect is improved, and the toxic or side effect and poor reaction during single administration is reduced.

The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with pomalidomide and dexamethasone.

The invention discloses an umbilical cord preservation fluid and an umbilical cord preservation method. The umbilical cord preservation fluid is prepared from 15-20 mmol of hyperbranched polyglycerol,99-101 mmol of lacturonic acid, 24-26 mmol of monopotassium phosphate, 4-6 mmol of magnesium sulfate, 4-6 mmol of adenosine, 2-4 mmol of glutathione reduction type, 6-10 mg of dexamethasone, 0.5-1.5mmol of allopurinol, 50-70 mmol of sucrose, 40-60 g of dextran, 18-22 mg of verapamil, 4-6 ml of sodium hydroxide and 19-21 ml of potassium hydroxide. When an umbilical cord is preserved , the cleanedumbilical cord is cut into small sections with the length of 3-5 cm, then immersed into a preservation liquid and preserved in an environment with the temperature of 3-5 DEG C. By adopting the preservation liquid, the problem that the umbilical cord cannot be preserved for a long time after being isolated can be effectively solved.

The invention discloses a method for inhibiting the growth and metastasis of solid tumor cells and a special pharmaceutical composition, and belongs to the field of animal cell proliferation and transformation. When ovarian cancer HEY cells or breast cancer MDA-MB-231 cells are induced, a culture medium is replaced after acting in high-concentration CoCl2, and after the cells are recovered, the treatment is repeated twice to obtain a sufficient number of cells with high invasion and metastasis ability; and the obtained cells are cultured in a culture medium without CoCl2, then the removed culture medium is added with a pharmaceutical composition prepared from dimethyl sulfoxide, dexamethasone, rosiglitazone, 3-isobutyl-1-methylxanthine for in-vitro induction, and when obvious lipid droplets are formed in tumor cell plasma, it indicates that the tumor cells have adipose differentiation. The method is designed to induce the tumor cell adipose differentiation and the purpose of inhibitingtumor cell growth is achieved. It is confirmed by animal experiments that the method is expected to be used for clinical treatment and metastasis inhibition of human solid tumors.

The invention discloses a method for promoting osteogenic differentiation of bone marrow mesenchymal stem cells. The method comprises the following steps of (1) culturing human bone marrow mesenchymalstem cells in a DMEM / F12 medium, and performing digestion with 0.25% pancreatin for passage when the cell fusion degree reaches 80-90%; and (2) inoculating a differential medium with the bone marrowmesenchymal stem cells obtained by subculture in the step (1), and carrying out induced differentiation, wherein the differential medium comprises the DMEM / F12 medium, 18-22 [mu]g / mL of insulin, 5-10ng / mL of dexamethasone, 40-50 [mu]g / mL of ascorbic acid, 15-23 [mu]g / mL of sulfobutyl-beta-cyclodextrin, 45-52 [mu]g / mL of betaine, 10-15 ng / mL of indium acetate and 50-60 [mu]g / mL of glutathione. According to the invention, the differential medium is inoculated with the bone marrow mesenchymal stem cells obtained through subculture, and the sulfobutyl-beta-cyclodextrin, the betaine and the indiumacetate are added into the differential medium to achieve a synergistic effect, so that the osteogenic differentiation efficiency of the bone marrow mesenchymal stem cells is effectively improved, the osteogenic differentiation time is shortened, and a guarantee is provided for clinical application of the bone marrow mesenchymal stem cells to tissue-engineered bone construction.

The invention relates to a composition for treating pruritus and acne and a preparation method thereof. The composition mainly comprises, by mass, 0.01-0.1% of dexamethasone acetate, 0.1-0.5% of chlorphenamine maleate, 2.5-10% of chloramphenicol, 12-25% of compound sulfamethoxazole and 64.4-85% of compound ketoconazole ointment.

A medicinal film for treating oral ulcer is composed of a plastics coated paper layer, a composite film layer, and a medicine layer as sandwich which is proportionally prepared from gentamycin sulfate, menonasal and dexamethasone acetate. Its preparing process includes preparing film slurry, preparing medicine slurry defoaming and preparing film.

The present invention provides a composite material for promoting or inducing osteogenesis in a biological organism. The composite material includes: A) an induced osteoblast differentiation inducing agent obtained by culturing chondrocytes capable of hypertrophication in a differentiation agent producing medium containing dexamethasone, β-glycerophosphate, ascorbic acid and a serum component; and B) a biocompatible scaffold. The present invention also provides a method of producing this composite material and a method of promoting or inducing osteogenesis in a biological organism.

The invention discloses a medicinal composition, which comprises pharmaceutically effective dose of tolazoline hydrochloride, gentamycin sulfate, ribavirin, dexamethasone sodium phosphate, chlorphenamine maleate and a pharmaceutical carrier. The medicinal composition can be used for treating various acute or chronic rhinitis, sinusitis, purulent rhinitis, rhinitis sicca, atrophic rhinitis, allergic rhinitis and the like.

Provided is a preparation method of a dexamethasone calcium phosphate hydrogel. By mixing a dexamethasone sodium phosphate solution with a Ca<2+> containing aqueous solution, the dexamethasone sodium phosphate solution and the Ca<2+> containing aqueous solution can spontaneously form the dexamethasone calcium phosphate hydrogel in a self-assembly mode. The preparation method of the dexamethasone calcium phosphate hydrogel has the advantages of being simple in preparation, quick in hydrogel forming and accurate and controllable in drug loading capacity.

The invention discloses drug-release type gel for treating fundus macular degeneration and a preparation method thereof. The drug-release type gel comprises an anti-angiogenesis drug, an inducing compound and gel and is characterized in that the inducing compound is used for increasing the permeation of the drug, and the gel attaches to the cornea during use and serves as the carrier of the drug;the anti-angiogenesis drug is selected from Lucentis or Compaq; the inducing compound is selected from optional one of dexamethasone, prednisone and cortisone or the combination of two of dexamethasone, prednisone and cortisone; the gel serving as the drug carrier is prepared by preparing a solution containing polydopamine and methacrylate gelatin, adding crosslinking agent N,N-methylene bisacrylamide and initiator potassium peroxydisulfate into the solution, and performing fixed-die forming to obtain the gel which does not contain the drug. The drug-release type gel has the advantages that non-invasive drug delivery is adopted, sustained drug release is achieved after the gel attaches to the cornea, and the anti-VEGF drug is allowed to act on the vitreous body by utilizing the permeability of the inducing compound.

The invention discloses Bishutong nasal drops for children. The Bishutong nasal drops are prepared by combining a liquid A with a liquid B which have equal volume, wherein the liquid A comprises raw materials in percentage by mass as follows: 3%-7% of houttuynia cordata, 0.5%-1.5% of bupleurum chinense, 0.5%-1.5% of biond magnolia flowers, 0.005%-0.008% of naphazoline, 0.8%-1% of sodium chloride, 0.8%-1.2% of methylparaben and 87.792%-94.395% of deionized water; the liquid B comprises raw materials in percentage by mass as follows: 3%-7% of houttuynia cordata, 0.04%-0.06% of chlorpheniramine, 0.008%-0.012% of dexamethasone, 0.08%-0.12% of adenosine triphosphate, 0.08%-0.13% of lysozyme, 0.8%-1% of sodium chloride, 0.8%-1.2% of methylparaben and 90.478%-95.192% of deionized water. The Bishutong nasal drops for children has reliable efficacy when treating rhinitis and sinusitis of children and is convenient to use, and the clinical total effective rate is 100%.

The invention discloses a medicine for preventing medicine-related osteonecrosis of the jaw. The medicine uses a DNA tetrahedron as an effective ingredient. Experiments show that the DNA tetrahedron can reverse the inhibitory effect of zoledronic acid, dexamethasone and other medicines on osteoclast, and can relatively well prevent medicine-related osteonecrosis of the jaw.

The invention provides a culture medium for inducing differentiation of dental pulp stem cells into osteoblasts. The culture medium comprises 4-5.5g / L of bovine serum albumin (BSA), 1.5mg / L of reducedglutathione, 0.08-0.12mmol / L of beta-mercaptoethanol, 0.08%-1.5%(V / V) of SITE, 0.8-1.2M / L of beta-glycerophosphoric acid, 15-25[mu]M / L of L-ascorbic acid, 0.5-1.2mM / L of dexamethasone and the balanceof low-sugar dulbecco's modified eagle medium (DMEM) culture medium added with an amino acid concentrated solution. The culture medium for inducing differentiation of dental pulp stem cells to osteoblasts is a serum-free culture medium, and the culture medium can be used to optimize a method for inducing differentiation of dental pulp stem cells to osteoblasts. The induction time is short and cost is low, and the invention provides a new selection for culture of seed cells in bone tissue engineering.

The invention relates to a method for improving osteogenic differentiation efficiency of human amniotic mesenchymal stem cells. The method adds an induction composition in the human amniotic mesenchymal stem cells, wherein the composition comprises 0.1-2g / L of hyaluronic acid, 0-200mg / L of prostaglandin receptor-2 selective agonist, 1-100nmol / L of dexamethasone, 0-10nmol / L of beta-glycerophosphate and 1-100mg / L of ascorbic acid. Compared with a conventional inducing method, the osteogenic differentiation efficiency of the human amniotic mesenchymal stem cells can be significantly improved, expression and activity of alkaline phosphatase are promoted, and expression of osteogenesis-related genes of RunX2, Osx, BSP, Ocn, ALP, Col1a1 and the like and formation of mineralized calcium nodules are enhanced. The method for improving the osteogenic differentiation efficiency of the human amniotic mesenchymal stem cells can be applied in osteogenic differentiation of the human mesenchymal stem cells, and applied in bone diseases of bone defects, bone trauma and the like.

The invention relates to a dexamethasone small-molecular hydrogel drug delivery system and a preparation method thereof. According to the invention, dexamethasone is subjected to derivatization by using 1,4-succinic anhydride or glutaric anhydride, such that a dexamethasone prodrug is formed. Through pH value regulation, the prodrug is subjected to auto-hydrolysis, such that dexamethasone drug molecules are released; the molecules are subjected to self-assembly spontaneously, such that the small-molecular hydrogel is formed. Specifically, dexamethasone 21 hydroxyl site derivatization is achieved by using 1,4-succinic anhydride (glutaric anhydride), such that gel-forming precursor molecules are obtained. The precursor molecules have good solubility, high drug load, and simple components. Through auto-hydrolysis, dexamethasone drug molecules can be released, and can be spontaneously self-assembled into the hydrogel. The process does not need to be driven by any chemical reagent. According to the system, drug molecules and derivatized drug are adopted as carriers, such that other carriers are not needed. Therefore, the dexamethasone novel delivery system provided by the invention assists in improving solubility and drug load of dexamethasone in water, and is potential to be developed into a novel preparation form of dexamethasone.